Concepedia
Statistics
Publications
37
Citations
4.5K
H-Index
25
Active since
1991
Affiliations
Boehringer Ingelheim (Canada)(Current)
Pfizer (United States)
Bristol-Myers Squibb (United States)
Boehringer Ingelheim (Egypt)
University of Toronto
Stephen W. Mason is an author at Boehringer Ingelheim (Canada) specializing in life sciences, pharmacology, and drug discovery.
Publications per year
1991–2025
An oral SARS-CoV-2 M <sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19
Dafydd R. Owen, Charlotte Allerton, Annaliesa S. Anderson et al. · Science · 2021 · 1.9K citations · Full text
Medicine, Infectious Diseases, Pharmacology +13
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19
Britton Boras, Rhys Jones, Brandon J. Anson et al. · Nature Communications · 2021 · 296 citations · Full text
Pharmacy, Infectious Diseases, Pharmacology +15
Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy
Cynthia L. Gay, Ronald J. Bosch, Justin Ritz et al. · The Journal of Infectious Diseases · 2017 · 221 citations · Full text
Life Sciences, Immunology, Pharmacology +17
Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1
Lee D. Fader, Éric Malenfant, Mathieu Parisien et al. · ACS Medicinal Chemistry Letters · 2014 · 180 citations · Full text
Pharmacy, Medicinal Chemistry, Pharmacology +17
Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19
Britton Boras, Rhys Jones, Brandon J. Anson et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2020 · 159 citations · Full text
1–5 of 37